Solid Biosciences Shares Up After Positive Results From Duchenne Drug Study, Prices $200 Million Offering
In This Article:
Solid Biosciences (SLDB) shares were up almost 34% in Tuesday trading after the company said a phase
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Terms and Privacy Policy